Drug Database
Back to search

Poland· PL-100210823

Skinoren Rosacea

A azelaic acid product containing acidum azelaicum, registered in Poland by LEO Pharma A/S. The same ATC class is registered in 12 of our 19 countries.

ATC D10AX03

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedSkinoren RosaceaATCD10AX03REGISTER NO.PL-100210823PACKS LISTED3CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about acidum azelaicumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Azelaic acid is registered in 12 of 19 countries.

Countries holding a registration under ATC D10AX03 (azelaic acid), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 7 of them publish a price we can compare per daily dose
Search azelaic acid products by name

Azelaic acid · ATC D10AX03

12 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Germany
  • Ireland
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Acidum azelaicum
Manufacturer
LEO Pharma A/S
Country
Poland (PL)
ATC code
D10AX03
ATC class
Azelaic acid
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 3

  • gtin
    05909990707829
  • gtin
    05909990707836
  • gtin
    05909990707843

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

5 interactions on record for azelaic acid.

Graded by severity as the source publishes them — 2 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check azelaic acid against other medicinesHow interaction checks work

Azelaic acid · interactions on record

5 records

  • 2 moderate
  • 3 info

Most severe, free to view

  • IsotretinoinD10AD04moderate
  • IsotretinoinD10BA01moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Azelaic acid in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All azelaic acid products

Authorised across Europe · EMA

The same active substance is authorised in 26 EEA countries. Names it is sold under:

  • Austria · Finacea, Skinoren
  • Belgium · Skinoren
  • Bulgaria · Скинорен, Финацеа
  • Cyprus · Skinoren
  • Czechia · Skinoren
  • Germany · Skinoren
  • Denmark · Finacea, Skinoren
  • Estonia · Finacea, Skinoren
  • Spain · Finacea, Zeliderm
  • Finland · Skinoren
  • France · Finacea, Skinoren
  • United Kingdom (Northern Ireland) · Finacea, Skinoren
  • Greece · Arbonid, Azelderm
  • Croatia · Skinoren
  • Hungary · Finacea, Skinoren
  • Ireland · Skinoren
  • Italy · Finacea, Skinoren
  • Lithuania · Finacea, Skinoren
  • Luxembourg · Skinoren
  • Latvia · Finacea, Skinoren
  • Norway · Finacea, Skinoren
  • Portugal · Skinoren
  • Romania · Skinoren
  • Sweden · Azelainsyra Evolan, Finacea
  • Slovenia · Skinoren
  • Slovakia · Finacea, Skinoren

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/540f64db-24e4-469d-9ced-58c0fcf306fb
GET /v1/drugs/540f64db-24e4-469d-9ced-58c0fcf306fb?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Żel",
  "source": "urpl",
  "strength": "150 mg/g",
  "packaging": "05909990707829 ¦ OTC ¦ Skasowane ¦ 51076\n1 tuba 5 g\n05909990707836 ¦ OTC ¦ Skasowane ¦ 51077\n1 tuba 15 g\n05909990707843 ¦ OTC ¦ 51079\n1 tuba 30 g",
  "substance": "Acidum azelaicum 15 g",
  "common_name": "Acidum azelaicum",
  "pl_product_id": "100210823",
  "pozwolenie_nr": "15570",
  "auth_procedure": "DCP",
  "authorisation_validity": "Bezterminowe"
}
API referenceMCP serverPlans

See everything about azelaic acid.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console